海尔生物2025年度归母净利润2.5亿元，下滑31.6%

Core Viewpoint - Haier Biomedical (688139.SH) reported a revenue of 2.33 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 2.0%, while the net profit attributable to shareholders decreased by 31.6% to 250 million yuan [1] Group 1: Revenue Breakdown - The company achieved overseas revenue of 840 million yuan, marking a year-on-year increase of 17.9%, which accounted for a record high of 36% of total revenue, up 5 percentage points from 2024 [1] - Revenue from the European region grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8% [1] - Domestic revenue reached 1.47 billion yuan, showing a decline of 5.5% year-on-year [1] Group 2: Industry Segmentation - Revenue from new industries (300832) constituted 48.5% of total revenue, with a year-on-year growth rate of 8.8% [1] - Revenue from the low-temperature storage industry accounted for 51.5% of total revenue, experiencing a year-on-year decline of 3.9% [1] - Following a positive growth in the third quarter, the low-temperature storage segment accelerated its recovery in the fourth quarter, indicating a gradual exit from the bottom [1]